Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings—a meta-analysis

被引：0
|
作者：
Karin Jordan
David G. Warr
Axel Hinke
Linda Sun
Paul J. Hesketh
机构：
[1] Martin-Luther- University Halle-Wittenberg,Department of Internal Medicine IV, Hematology/Oncology
[2] Princess Margaret Hospital,Department of Hematology Oncology
[3] WiSP Wissenschaftlicher Service Pharma GmbH,undefined
[4] Merck & Co.,undefined
[5] Inc.,undefined
[6] Lahey Hospital & Medical Center,undefined
来源：
Supportive Care in Cancer | 2016年 / 24卷
关键词：
Chemotherapy-induced nausea and vomiting; Emetogenicity; Neurokinin-1 receptor; Antiemetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1941 / 1954
页数：13
相关论文
共 50 条
  • [41] Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis
    Jin, Y.
    Sun, W.
    Gu, D.
    Yang, J.
    Xu, Z.
    Chen, J.
    EUROPEAN JOURNAL OF CANCER CARE, 2013, 22 (01) : 41 - 50
  • [42] Meta-analysis of safety and efficacy of rolapitant, NK-1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting
    Ahmed, Hussien
    Hammad, Ali Mohamed
    Abushouk, Abdelrahman Ibrahim
    Zidan, Mohamed
    Salem, Mohamed
    Negida, Ahmed
    Abdel-Daim, Mohamed M.
    CURRENT PROBLEMS IN CANCER, 2018, 42 (02) : 241 - 255
  • [43] Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis
    Jordan, Karin
    Blaettermann, Luisa
    Hinke, Axel
    Mueller-Tidow, Carsten
    Jahn, Franziska
    SUPPORTIVE CARE IN CANCER, 2018, 26 (01) : 21 - 32
  • [44] Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?—a systematic review and meta-analysis
    Karin Jordan
    Luisa Blättermann
    Axel Hinke
    Carsten Müller-Tidow
    Franziska Jahn
    Supportive Care in Cancer, 2018, 26 : 21 - 32
  • [45] Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis
    Yokoe, Takamichi
    Hayashida, Tetsu
    Nagayama, Aiko
    Nakashoji, Ayako
    Maeda, Hinako
    Seki, Tomoko
    Takahashi, Maiko
    Takano, Toshimi
    Abe, Takayuki
    Kitagawa, Yuko
    ONCOLOGIST, 2019, 24 (06): : E347 - E357
  • [46] Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: Summary of clinical trials
    Navari, RM
    CANCER INVESTIGATION, 2004, 22 (04) : 569 - 576
  • [47] Use of Neurokinin-1 Receptor Antagonists in Patients Receiving Moderately or Highly Emetogenic Chemotherapy
    Rogers, Miriam P.
    Blackburn, Linda
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2010, 14 (04) : 500 - 504
  • [48] Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy
    Molassiotis, Alex
    Nguyen, Allison Martin
    Rittenberg, Cynthia N.
    Makalinao, Alex
    Carides, Alexandra
    FUTURE ONCOLOGY, 2013, 9 (10) : 1443 - 1450
  • [49] Moxibustion for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis
    Huang, Ziling
    Qin, Zongshi
    Yao, Qin
    Wang, Yuanxuan
    Liu, Zhishun
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2017, 2017
  • [50] Phase 2 Trial Results With the Novel Neurokinin-1 Receptor Antagonist Casopitant in Combination With Ondansetron and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy
    Arpornwirat, Wichit
    Albert, Istvan
    Hansen, Vincent L.
    Levin, Jeremey
    Bandekar, Rajesh R.
    Grunberg, Steven M.
    CANCER, 2009, 115 (24) : 5807 - 5816
12345